Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Abstract 14284: Anticoagulant Effects of Edoxaban in Cancer and Non-Cancer Patients With Venous Thromboembolism
View through CrossRef
Introduction:
Edoxaban, a direct oral anticoagulant (DOAC), is established as an anticoagulant medication in the treatment of venous thromboembolism (VTE) and suppression of VTE recurrences. While VTE recurrences in patients with cancer is greater than those in patients with non-cancer in spite of DOACs use, the reason is unclear. Anticoagulant effects of DOACs are not monitored because of less individual variability on their pharmacological effects and a short half-time. Although the plasma concentration of edoxaban correlates with prothrombin time (PT) and activated partial thromboplastin time (APTT) in healthy adults. PT and APTT are prolonged up to 5 hours after administration of edoxaban.
Hypothesis:
We hypothesized that anticoagulant effects of edoxaban are inhibited in patients with cancer and measured PT and APTT to assess its anticoagulant effects.
Methods:
This study is prospective observational study conducted in 12 hospitals. Patients with VTE taking edoxaban for treatment were included. PT and APTT were measured at 5-hours after first administration of edoxaban, and also measured at optional time after 7 days and/or 30 days. D-dimer, prothrombin fragment 1+2, and thrombin-antithrombin complex were measured once as coagulation markers.
Results:
Two hundred forty-three patients were included in the study, and 80 patients were with cancer. PT and APTT were measured at 465 points. PT and APTT at 5-hours after first administration of edoxaban were not significantly different between patients with cancer and non-cancer (17.1 ± 0.4 vs. 16.8 ± 0.3 seconds; PT, 35.1 ± 0.6 vs. 34.5 ± 0.5 seconds; APPT). PT values at 5-hours after first administration were prolonged compared with those at before administration in patients with cancer and non-cancer (13.8 ± 0.6 and 13.8 ± 0.4 seconds; before administration). Other coagulant markers were not significantly different between patients with cancer and non-cancer.
Conclusions:
Anticoagulant effects of edoxaban do not differ between patients with cancer and non-cancer, and those effects are sufficient. Greater VTE recurrences in patients with cancer may be due to hypercoagulable state by cancer, but not lowering anticoagulant effects of edoxaban.
Ovid Technologies (Wolters Kluwer Health)
Title: Abstract 14284: Anticoagulant Effects of Edoxaban in Cancer and Non-Cancer Patients With Venous Thromboembolism
Description:
Introduction:
Edoxaban, a direct oral anticoagulant (DOAC), is established as an anticoagulant medication in the treatment of venous thromboembolism (VTE) and suppression of VTE recurrences.
While VTE recurrences in patients with cancer is greater than those in patients with non-cancer in spite of DOACs use, the reason is unclear.
Anticoagulant effects of DOACs are not monitored because of less individual variability on their pharmacological effects and a short half-time.
Although the plasma concentration of edoxaban correlates with prothrombin time (PT) and activated partial thromboplastin time (APTT) in healthy adults.
PT and APTT are prolonged up to 5 hours after administration of edoxaban.
Hypothesis:
We hypothesized that anticoagulant effects of edoxaban are inhibited in patients with cancer and measured PT and APTT to assess its anticoagulant effects.
Methods:
This study is prospective observational study conducted in 12 hospitals.
Patients with VTE taking edoxaban for treatment were included.
PT and APTT were measured at 5-hours after first administration of edoxaban, and also measured at optional time after 7 days and/or 30 days.
D-dimer, prothrombin fragment 1+2, and thrombin-antithrombin complex were measured once as coagulation markers.
Results:
Two hundred forty-three patients were included in the study, and 80 patients were with cancer.
PT and APTT were measured at 465 points.
PT and APTT at 5-hours after first administration of edoxaban were not significantly different between patients with cancer and non-cancer (17.
1 ± 0.
4 vs.
16.
8 ± 0.
3 seconds; PT, 35.
1 ± 0.
6 vs.
34.
5 ± 0.
5 seconds; APPT).
PT values at 5-hours after first administration were prolonged compared with those at before administration in patients with cancer and non-cancer (13.
8 ± 0.
6 and 13.
8 ± 0.
4 seconds; before administration).
Other coagulant markers were not significantly different between patients with cancer and non-cancer.
Conclusions:
Anticoagulant effects of edoxaban do not differ between patients with cancer and non-cancer, and those effects are sufficient.
Greater VTE recurrences in patients with cancer may be due to hypercoagulable state by cancer, but not lowering anticoagulant effects of edoxaban.
Related Results
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
P4464Significative role of edoxaban on endotelial cell functions
P4464Significative role of edoxaban on endotelial cell functions
Abstract
Background
Edoxaban is a new oral anticoagulant with factor X activated (FXa) inhibition properties. It is approved for...
Direct costs for treatment of venous thromboembolism complication 90-day after surgery
Direct costs for treatment of venous thromboembolism complication 90-day after surgery
Study object: Describe the direct treatment costs due to venous thromboembolism complications 90 days after surgery by using national health insurance reimbursement database. Patie...
Incidence of thromboembolism and thromboprophylaxis in medical patients admitted to specialized hospital in Ethiopia using Padua prediction score
Incidence of thromboembolism and thromboprophylaxis in medical patients admitted to specialized hospital in Ethiopia using Padua prediction score
Introduction:
Venous thromboembolism is a major cause of mortality and morbidity among hospitalized patients and thromboprophylaxis is one of the key strategies...
Association of Anticoagulant Therapy with Bleeding in Patients with Chronic Liver Disease: A Case-Cross over Study Using the National Veterans Health Administration Database
Association of Anticoagulant Therapy with Bleeding in Patients with Chronic Liver Disease: A Case-Cross over Study Using the National Veterans Health Administration Database
Background:
Patients with chronic liver disease (CLD) are at a higher risk of venous thromboembolism (VTE) i.e., deep venous thrombosis or pulmonary embolism {Amb...
In-hospital mortality and associated factors among patients admitted with venous thromboembolism at selected public hospitals of Harar Town, Eastern Ethiopia
In-hospital mortality and associated factors among patients admitted with venous thromboembolism at selected public hospitals of Harar Town, Eastern Ethiopia
Background: Venous thromboembolism is the third most common cause of cardiovascular death and is responsible for more than 3 million deaths annually worldwide. Despite high rates o...
Outcomes of Venous Thromboembolism in Hospitalized Non-Hodgkin Lymphoma Patients: Analysis from the Nationwide Inpatient Sample Database
Outcomes of Venous Thromboembolism in Hospitalized Non-Hodgkin Lymphoma Patients: Analysis from the Nationwide Inpatient Sample Database
Abstract
Introduction:
Venous Thromboembolism (VTE), which includes deep venous thrombosis (DVT) and pulmonary embolism (PE), is one of the major caus...
Edoxaban monitoring strategy using chromogenic anti-Xa assays among patients with atrial fibrillation
Edoxaban monitoring strategy using chromogenic anti-Xa assays among patients with atrial fibrillation
Abstract
Introduction
Edoxaban, a direct oral anticoagulant for atrial fibrillation (AF) patients, reduces stroke and systemic e...